Today's Daily Dose brings you news about Akero's NASH study update; Axsome Therapeutics' major depressive disorder trial results; CEL-SCI's near-term catalyst; BioMarin's promising results of achondroplasia drug candidate; Wave Life Sciences decision to discontinue the development of DMD drug candidate and more.
from RTT - Biotech https://ift.tt/2rJBQSx
via IFTTT
No comments:
Post a Comment